沙库巴曲缬沙坦钠治疗心肾共病的研究进展
Research Progress on Sacubitril-Valsartan in the Treatment of Cardiovascular Diseases and Chronic Renal Diseases

沙库巴曲缬沙坦钠用于治疗心力衰竭，近年来研究表明其在心肾共病治疗上有很好的疗效和安全性。其双重靶点作用机制——心衰患者神经内分泌过度激活弱化，可以一定程度上改善肾血流、降低血压，为心肾双打击患者带来获益。临床试验与多中心临床结果显示，使用沙库巴曲缬沙坦钠治疗的心衰合并心肌病的患者不仅心功能得到改善，而且肾功能也得到改善。这样为心肾共病的患者选择新的治疗策略，它的独特的心肾保护机制使得心肾共病患者整体获益，但也需要更多的临床研究来证实其安全性及长期用药的有效性，未来的研究方向应该致力于其长期使用对不同的心肾疾病患者的有效性及安全性，并考虑是否进行个体化治疗。未来会有越来越多的临床研究出现，沙库巴曲缬沙坦钠在未来也许能够成为新的治疗心肾共病的有效治疗药物之一。
Sacubitril-valsartan is a drug for the treatment of heart failure, and recent studies have shown significant efficacy and safety in the treatment of cardiovascular diseases and chronic renal diseases. The dual-target mechanism of action of the drug weakens the neuroendocrine activation of patients with heart failure, and at the same time can increase renal blood flow and reduce blood pressure to a certain extent, which brings benefits to patients with a double blow to the heart and kidney. The results of clinical trials and multicenter clinical trials have shown that patients treated with sacubitril-valsartan sodium can also observe significant improvements in kidney function while improving cardiac function. This discovery provides a new therapeutic strategy, and its unique cardiorenal protective mechanism provides new hope for the comprehensive management of cardiovascular diseases and chronic renal diseases. Nevertheless, more clinical studies are needed to verify the safety and efficacy of its long-term application. Future research should focus on its long-term efficacy and safety, as well as its application in different types of heart and kidney diseases, and explore the development of individualized treatment options. With the deepening of more research, sacubitril-valsartan is expected to become one of the effective drugs for the treatment of cardiovascular diseases and chronic renal diseases, and it will provide patients with a safer and more effective treatment option.